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Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Malignancy is one 
of the most common causes of death in the world. T2DM is one of the risk factors for malignancy. This is caused by 
an increase in blood glucose levels (hyperglycemia) which will cause tissue hypoxia which can lead to malignancy. 
The cell adaptation response to hypoxia is relaxed by a marker called hypoxia-inducible factor-1 alpha (HIF-1α), 
where a condition converts hyperglycemia to a loss of cellular response to hypoxia in most complications of diabetes. 
AIM: The aim of this study was to determine level HIF-1α at T2DM with malignancy, where this study used the 
samples of the T2DM patients with malignancy and T2DM without malignancy. 
METHODS: The cross-sectional study design used the 89 samples of DM patients with and without malignancy 
who attended Murni Teguh Hospital in Medan of Indonesia country. The inclusion criteria of the samples were all the 
patients diagnosed with T2DM with or without malignancy, both the sexes. Body mass index, blood pressure, disease 
history, and socioeconomic status were recorded. The laboratory parameters, including fasting blood sugar (FBS) 
and HbA1c, were examined by Murni Teguh Hospital Laboratory and HIF-1α; we examined by ELISA methods in the 
laboratory Medical Faculty, Sumatera Utara Universitas. 
RESULTS: In this study, we found that there was no significant correlation between HIF-1α with FBS and HbA1c 
(p > 0.005), but we found that there was a significant correlation HbA1c with FBS (p < 0.005).
CONCLUSION: The results of the study revealed HIF-1α at the both of the group of the samples even in the relative 
small amounts until a large amounts in the serum, but we found that there was no correlation significantly between 
HIF-1α and glycemic index (HbA1c and FBS), while there was correlation significantly between Hba1c and FBS.
Introduction
Diabetes mellitus (DM) is a chronic metabolic 
disease caused by the body’s inability to produce insulin 
hormone as needed or due to the ineffective use of 
insulin or both. This is characterized by high blood sugar 
levels (hyperglycemia). At present, there is an increase 
in the prevalence of DM throughout the world. DM is 
known as a key factor contributing to the development 
of malignancies from solid organs, including the liver, 
pancreas, rectal colon, breast, endometrium, uterus, 
and bladder [1]. In 2013, there were 382 million people 
in the world aged 40–59 years suffering from DM, and it 
is estimated that it will continue to increase every year. 
Regional International Diabetes Federation data show 
that Southeast Asia is ranked the second-highest in the 
world with a total DM population of 72 million. In 2035, 
it is estimated that this figure will increase by 70.6% 
to 122.8 million; this increase in the prevalence of DM 
occurs throughout the world in both developed and 
developing countries [2], [3].
The number of diabetics in Indonesia is ranked 
7th in the world. At present, the prevalence of diabetes in 
Indonesia, which doctors have diagnosed, is 1.4%, this 
number is expected to continue to increase (Riskesdas, 
2013). The WHO estimates that 21,527,000 Indonesians 
will suffer from DM by 2030 [4]. DM is characterized 
by defects in hypoxia-induced neovascularization in 
the myocardium, skeletal muscle, nerves, and skin. 
Inadequate collateral vessel formation in response 
to ischemia increases cardiovascular morbidity and 
mortality in diabetic patients [5]. DM and malignancy 
are frequently diagnosed in the same individual [6]. 
The mechanism for the diabetes-cancer link has been 
hypothesized to be mainly related to hormonal insulin 
and insulin-like growth factor (IGF)-1, inflammatory, 
or metabolic (hyperglycemia) characteristics of the 
DM and even to certain treatments [7]. Antidiabetic 
medications may have effects on the risk of cancer. 
Many studies found that diabetes was consistently 
related to increased risk for a broad variety of 
malignancies, and the prospective researches reported 
that there was a relation of increased blood glucose with 
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increased overall cancer incidence and that postulated 
as a linear trend of increased blood glucose levels and 
cancer risks [8]. Several large cohort and case–control 
studies have found a positive relationship between 
hyperglycemia and the risk of cancer [9] and the other 
researches that a meta-analysis comprising 30 cohort 
studies showed that diabetes was associated with an 
increase in the risk of colorectal cancer [10], [11].
Cancer occurs in a condition, where the cell 
has lost its normal control and mechanism, resulting 
in abnormal growth [12]. Although the science is 
increasingly sophisticated, until now, it is not known 
with certainty the main cause of breast cancer, 
which is estimated to be very multifactorial [13]. 
Diabetes with malignancy is a common disease 
with extraordinary health impacts throughout the 
world [14]. Epidemiological evidence showed that 
people with diabetes have a significantly higher risk of 
developing malignancy [15]. Type 2 diabetes mellitus 
(T2DM) and malignancy have many risk factors, but 
the potential biological relationship between the two 
diseases is not fully understood. Moreover, evidence 
from observational studies showed that some drugs 
used to treat hyperglycemia are associated with 
an increase or decrease in cancer risk; [16] there 
are a variety of antidiabetic interventions, including 
sulfonylureas, α-glucosidase inhibitors, biguanides, and 
thiazolidinediones (TZDs) [17] that increase the level of 
circulating insulin, thereby reducing hyperglycemia by 
various mechanisms. Metformin inhibits cell proliferation 
and induces apoptosis in cancer cell lines [18], whereas 
metformin and other biguanides decrease the cancer 
incidence [19] that some confounding factors are 
directly related to the clinical diversity of diabetes 
levels at the level of metabolic control, duration of 
diabetes, antidiabetic therapy profile, and the presence 
of complications or comorbidities [19]. A number of 
the factors that contribute to the increased risk of 
developing cancer in T2DM include hyperglycemia, 
insulin resistance, hyperinsulinemia, increased levels 
of IGF-1, dyslipidemia, cytokines, increased leptin, and 
decreased levels of adiponectin [20], [21], [22].
Recently, many studies improved that DM is 
often associated with hypoxia which damages induced 
neovascularization during the process of ischemia 
and other forms of cell response and adaptive tissue 
to low oxygen levels [23]. Hyperglycemia seems to be 
the driving force for such deregulation. Recent data 
on destabilization of hypoxia-inducible factor-1-alpha 
(HIF-1α) are likely to be events that hyperglycemia 
loss cellular response to hypoxia in most diabetes 
complications [24]. HIF-1α was a master regulator 
that mediates the cellular response to hypoxia [25] so 
that has been proven that HIF-1α plays a role in the 
pathogenesis of malignancy too. Due to that, this aim 
study wants to know how the correlation about the 
HIF-1α with the control glycemic in type 2 mellitus 
patients with malignancy and without malignancy.
Materials and Methods
Subjects
We included 89 of the samples, consecutive 
T2DM with malignancy and T2DM without malignancy, 
between January and July 2019, who attended to 
Murni Teguh Hospital in Medan, North Sumatera, 
Indonesia, according to ADA and the WHO guidelines. 
The samples was composed of all T2DM with or without 
malignancy, both male and female, without the exception 
the age and treatment. Exclusion criteria were type 1 
DM and severe disease. Physical examinations were 
performed to record patient demographics, including 
height, weight, body mass index (BMI), and blood 
pressure. Biochemical tests were done as fasting 
blood sugar (FBS) and HbA1c. All participants were 
provided written informed consent at the visits and 
explain of the examination for the samples and this 
study was in compliance with the Declaration of 
Helsinki. Our study was approved by our Institutional 
Health Research Ethics Committee with number 484/
TGL/KEPK FK USU-RSUP HAM 2019.
Biochemical measurements
Before the blood samples were collected at 
a visit to the outpatient clinic, the samples must fast 
overnight. The blood of the samples was centrifuged 
at 3000 rpm at 4°C for 15 min. The supernatants were 
decanted and frozen at −80°C until assayed. FBS and 
HbA1c were measured using standard methods. FBS 
was examined by the machinery portable measuring 
instrument (Gluco DR) and HbA1c was measured by 
the HPLC method. The plate has been pre-coated 
with human HIF-1α antibody. HIF-1α presents in 
the sample is added and binds to antibodies coated 
on the wells instead use then biotinylated human 
HIF-1α. The antibody is added and binds to HIF-1α 
in the sample. The substrate solution is then added, 
and color develops in proportion to the amount of 
human HIF-1α. The reaction is terminated by the 
addition of acidic stop solution, and absorbance is 
measured at 450 nm. Intra-assay and inter-assay 
coefficients of variation for HIF-1α were <8% and 
<10%, respectively.
Statistical analysis
SPSS version 24.0 (SPSS Inc., Chicago, 
Illinois) statistical software was used for statistical 
analysis. All the variables in this sample of the study 
were tested by Shapiro–Wilk, the normal distribution 
variables (p > 0.005) were tested by parametric 
correlation test, but the abnormal distribution variables 
(p < 0.005) were tested by non-parametric test.
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Results
All the subjects of this study 89 samples, 
average 38–77 years old, consist of 36 males (40.4%) 
and 53 females (59.6%). The subjects of this study 
were 40 samples with T2DM with malignancy and 49 
samples without malignancy. The characteristics of 
the subjects of the study are included in Tables 1 and 
2, BMI of the Group 1 was 24.89 ± 4.59 kg/m2 that 
subjects were normal and preobese group; according 
to the WHO, the BMI of the subjects at the samples 
with T2DM without malignancy was 25.78 ± 4.59 kg/
m2 that subjects were a normal and preobese group. 
Table 1. Characteristic of samples of diabetes mellitus Type 2 
with malignancy (group 1) (n=40)
Parameter Minimum Maximum Mean SD
Age (years) 37 73 56.90 8.75
BMI (kg/m2 ) 19.53 37.78 24.89 4.59
FBS (mg/dl) 83 635 260.45 105.55
Hba1c (%) 2.4 12.70 7.57 2.26
HIF-1α (ng/ml) 0.0 17.80 1.67 3.73
The minimum of the FBS levels in the subjects with 
T2DM with malignancy was 83 mg/dl and the maximum 
was 635 mg/dl and the minimum of the FBS levels of 
the subjects with T2DM without malignancy was 87 
mg/dl and the maximum of the FBS levels was 500 
mg/dl. In the both of the samples group we found 
average hyperglycemia. The mean of the HbA1c value 
in the subjects of type DM with malignancy was 7.57 
± 2.26% which should be good and the bad level of 
the glycemic control. However, the mean of the HbA1c 
of the subject of T2DM without malignancy was 9.34 
± 1.62% which means that all the subjects had bad 
glycemic control. T2DM with malignancy found the 
HIF-1α in relative small (0.000) accounts in the plasma 
until the high concentration of HIF-1α (17.80 ng/ml). In 
the samples of T2DM without malignancy we found 
relative small HIF-1α levels in the plasma (0.00) and 
the highest of the HIF-1α levels in the plasma (3.16 ng/
mL). All the subjects were found that the HIF-1α levels 
were highest at the subjects of DM with malignancy. 
But by statistics, we found that there was no significant 
difference between HIF-1α at the subjects at T2DM with 
malignancy without malignancy (p = 0.005).
In this study, we found that there was no 
significant correlation between HIF-1α with FBS and 
HbA1c (p > 0.005), but we found that there was a 
significant correlation HbA1c with FBS (p < 0.005).
Discussion
Hyperglycemia was the characteristic of 
T2DM, and the previous studies with T2DM it was found 
increasing HIF-1α levels, indicated a state of the severity 
of DM [26]. T2DM with retinopathy was associated with 
the increased plasma HIF-1α levels and indicate that 
diabetic retinopathy will occur in the future and at the 
advanced retinopathy, because the average HIF-1α 
level was higher than that of the mild retinopathy group. 
Low or normal plasma HIF-1a levels depended on 
the degree of diabetic retinopathy [27]. HIF-1α levels 
do not have a relationship with microalbuminuria and 
interactions with microalbuminuria with retinopathy [28]. 
Research by Zhang et al. said that hyperglycemia 
was significantly increasing HIF-1α [29]. Other 
studies showed that hyperglycemia and hypoxia were 
suspected to play a role in the pathophysiology of DM 
complications, due to the defective response of cells 
to low oxygen pressure [30]. Research by Sergiu-Bog 
and Catrina et al. said that primarily endothelial cells 
and dermal fibroblasts, hyperglycemia interferes with 
the function of induced hypoxia factor-1 alpha, which 
is a transcriptional factor in response to cell adaptation 
to the hypoxia process [31]. The occurrence of hypoxia 
is due to inadequate perfusion in adipose that has 
hyperplasia or hypertrophy. DM has a higher risk of 
malignancy compared to populations that do not have 
diabetes. Diabetes the risk of the some malignancies 
and also the negative prognosis affects people with DM 
after the diagnosed [32]. Patients with diabetes have 
a higher risk than the population without diabetes to 
suffer from cancer of the urinary tract, liver, bile ducts, 
pancreas, colon, endometrium, and kidneys [33], [34].
Long before HIF-1α was discovered in 1927 
by Warburg et al. the observation that a malignancy 
occurred that produce high levels of lactate even in 
the presence of abundant oxygen [35]; he attributed 
this unusual form of aerobic glycolysis to mitochondrial 
injury. This glycolytic shift has been observed in 
dozens of cancers where rates of glycolysis may be 
200 times higher than in non-cancer cells [36]. The 
Non-parametric correlation
Correlations HIF-1α Hba1c
Spearman’s rho
HIF-1α
Correlation coefficient 1.000 ‒0.111
Sig. (two-tailed) - 0.301
N 89 89
Hba1c
Correlation coefficient ‒0.111 1.000
Sig. (two-tailed) 0.301 -
N 89 89
Parametric correlation
Correlations FBS Hba1c
Spearman’s rho
FBS
Correlation coefficient 1.000 0.292**
Sig. (two-tailed) - 0.005
N 89 89
Hba1c
Correlation coefficient 0.292** 1.000
Sig. (two-tailed) 0.005 -
N 89 89
**Correlation is significant at the 0.01 level (two-tailed).
Table 2. Characteristic of samples of diabetes mellitus type 2 
without malignancy (group 2) (n=49)
Parameter Minimum Maximum Mean SD
Age (years) 38 77 59.31 8.1
BMI (kg/m2) 18.55 41.84 25.78 4.59
FBS (mg/dL) 87 500 229.76 89.46
Hba1c (%) 6.10 14 9.34 1.62
HIF-1α (ng/mL) 0.0 3.16 0.69 0.84
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previous studies found that hypoxia activated HIF-1α 
which results in the control of the post-ischemia 
revascularization process [37]. Recent research has 
revealed that destabilization of HIF-1α was most likely 
an event that transduced that hyperglycemia into a 
loss of cellular response to hypoxia in most diabetic 
complications [38]. HIF-1α levels decrease on biopsy 
of foot ulcers in patients with DM compared to venous 
ulcers that have the same hypoxic environment, but are 
not exposed to hyperglycemia.  Decreased regulation 
of HIF-1α in response to hyperglycemia also appears 
to be responsible for the decrease in collateral growth 
triggered by myocardial ischemia in patients with DM 
[35]. Research by Jiang et al. found that a significantly 
increased HIF-1α levels in diabetics who were carried 
out in a cohort study, and followed by increased of the 
vascular endothelial growth factor (VEGF) [11]. This 
study also showed a positive correlation between serum 
VEGF and HIF-1α in patients with DM, presumably 
due to extensive HIF-1α role in regulating VEGF 
expression in diabetes. It was shown that HIF-1α, as 
a master regulator of cell response to hypoxic stress, 
plays important roles in breast cancer metastasis too 
[39]. We reported in this study this point of view by 
demonstrating that hypoxia/HIF-1 induces cancer stem-
like cells by Jagged2 or mediates paracrine signaling 
between breast cancer cells and mesenchymal stem 
cells to promote metastasis [40]. However, this study 
did not show a significant correlation between HIF-1α 
with HbA1c or with FBS (p > 0.005). However, the 
results showed a significant correlation between HbA1c 
and FBS (p < 0.005), where r2 = 0.087, where FBS 
affected HbA1c 8.7%, and the rest was influenced 
by other factors. However, almost all samples of the 
study were found to have HIF-1α levels with different 
concentration levels, where the presence of HIF-1α 
was indicated the presence of hypoxic areas. In our 
study, we only classified the samples in two groups of 
Type 2 DM - with malignancy and without malignancy. 
However, both groups showed the levels of HIF-1α with 
different concentrations with the minimum values in the 
groups being the same, but the maximum values in the 
two groups were very different, where the maximum 
values in the T2DM group were much higher than those 
in the DM group without malignancy [41], [42].
Conclusion
It can be concluded that high levels of HIF-1α 
in DM samples with malignancy indicate the severity 
of the disease and the malignancy process suffered by 
the sample due to the ongoing hypoxia process. In spite 
of the high levels of the DM group without malignancy, 
we cannot conclude that they will experience a 
malignancy process, as well as there are still many 
factors involved. The higher levels of HIF-1α from 
the samples will experience a higher risk of getting a 
disease complication compared to the HIF-level with 
low 1α.
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